Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mylotarg in newly diagnosed pediatric AML
NCT00372593Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Aug 2006
- Primary completion
- Aug 2013
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Children's Oncology Group. Started Aug 2006; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00372593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00372593.